Bank of America started coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report issued to clients and investors on Thursday, October 17th, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the company. Citigroup set a $150.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Piper Jaffray Companies set a $180.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 6th. Royal Bank of Canada restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 18th. Robert W. Baird set a $165.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 30th. Finally, ValuEngine upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $159.00.
Shares of NASDAQ:ALXN traded up $2.74 on Thursday, hitting $110.79. The company’s stock had a trading volume of 1,255,600 shares, compared to its average volume of 1,803,421. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. Alexion Pharmaceuticals has a 1 year low of $92.56 and a 1 year high of $141.86. The company has a market capitalization of $23.73 billion, a PE ratio of 15.63, a PEG ratio of 1.02 and a beta of 1.65. The company has a 50-day simple moving average of $102.45 and a 200 day simple moving average of $115.69.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the company posted $2.02 earnings per share. The firm’s revenue was up 23.0% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals will post 9.41 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of ALXN. Steward Partners Investment Advisory LLC purchased a new stake in Alexion Pharmaceuticals during the second quarter valued at $28,000. Redhawk Wealth Advisors Inc. bought a new stake in Alexion Pharmaceuticals during the second quarter valued at about $29,000. Investors Research Corp grew its holdings in Alexion Pharmaceuticals by 52.0% during the third quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 104 shares during the period. Ossiam bought a new stake in Alexion Pharmaceuticals during the second quarter valued at about $32,000. Finally, Capital Bank & Trust Co grew its holdings in Alexion Pharmaceuticals by 355.9% during the second quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 210 shares during the period. Institutional investors own 94.68% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: What is the Dividend Aristocrat Index?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.